▎WuXi AppTec Content Team Report
Public information shows that several Chinese medical device companies announced new financing progress in October.. By combing through the product pipelines of these companies, we found that theyThe R&D products includeExoskeleton robots, AI-assisted pulmonary embolism diagnostic products, life-support products such as artificial hearts, innovative MagWave series products, brain-computer interface devices, neuromodulation medical devices, and precision interventional diagnostic and therapeutic products for泛血管 (pan-vascular) applications.etc.,Is expected to in the future forIndividuals with motor dysfunction caused by nerve injuries, patients with heart and lung failure, and patients with pulmonary embolism and lung diseases....and other new diagnostic and treatment methods.
Note:This table is from "MedView"》According to publicly available information, this is an incomplete statistic.Statistical Period:2023/9/1-2023/9/29。If there are any omissions, please feel free to add.
This article will share the basic information of eight rising companies based on the news release from the company's official website, for readers' reference only.
RoboCT
R&D Field: Exoskeleton Robot Technology
On October 7, RoboCT announced the introduction of international investors.Pappas Capital, while obtaining the original shareholdersYuhang National InvestmentThe continuous support. RoboCT was founded in 2017 and is committed to core algorithms and core components, includingExoskeleton RobotResearch and Application of Technology,To BenefitThose with motor dysfunction and mobility impairments caused by nerve damageAs a Mission。The company'sPediatric Exoskeleton ProductsThe KidGo series of rehabilitation exoskeletons have obtained the Class II medical device registration certificate from the China National Medical Products Administration (NMPA).This is an intelligent rehabilitation robot device specifically designed for children's rehabilitation. Through interactive gaming, it guides children wearing the device to perform repetitive and correct walking exercises, thereby correcting abnormal gait and enhancing their lower limb autonomous walking ability.
Oxygen Rich Medical
R&D Field: Pulmonary Embolism Auxiliary Diagnostic Products
On October 8, Nanjing Oxygen Rich Intelligent Medical Technology Co., Ltd. announced the completionThe first round of seed financing,ByNanjing Juyi TechnologyLeading investment.Nanjing Oxygen Rich Intelligent Medical Technology Co., Ltd. was founded in 2022, jointly established by a multidisciplinary team from Beijing Chaoyang Hospital and the artificial intelligence team from Southeast University.Based on an innovative diagnostic-grade pulmonary vascular intelligent map, an artificial intelligence diagnostic aid decision system for pulmonary embolism has been developed., aiming to address industry pain points such as the high proportion of misdiagnosis and missed diagnosis in pulmonary embolism.It is reported that the system can assist in the diagnosis of acute and chronic pulmonary embolism.，And it can fully cover the screening needs for pulmonary embolism and lung diseases.R&D Field: Life Support Products such as Artificial Hearts
News on October 8, LifeShield Medical announced the completionOver 100 Million Yuan in Financing. This round of financing was led bySherpa Venture CapitalAndYuanfeng CapitalCo-led by, existing investorsProxima VenturesContinue to invest,Shanghai Lingang Lanwan CapitalFollow-up Investment.LifeShield is a Sino-German collaborative medical device company. Its predecessor, Suzhou Lifeshield Medical, was established in 2018 and focuses on the field of extracorporeal and intracorporeal life support.LifeShieldThe company's core product pipeline is developed using its globally innovative blood pump platform technology.Focus on Innovative Therapies in the Field of Heart and Lung Failure, its product pipeline includes a new generation of interventional artificial heart systems (pVAD), stacked membrane-typeExtracorporeal Membrane Oxygenation (ECMO)、A carbon dioxide removal system (ECCO2R) specifically developed for severe COPD patients, etc.R&D Field: Magnetic Wave Knife Series Innovative Products
News on October 10: Shen De Non-Invasive Era announced the completion of nearly 200 million RMB in D-round financing. This round of financing was led byZhujii Huirii Yingtian, Hefei Industry Investment Phase II Fund, Tianjin Shenxin Jincheng, Ningbo Jinming ChuangjiaCo-investment. It is reported that Shen De Non-invasive Era, established in 2013, has built an innovative shared technology platform for "magnetic wave knife" and possesses continuous innovation capabilities in the "magnetic wave knife" field. The company is committed to tackling N treatment areas including the nervous system, body tumors, gynecology, andrology, and orthopedics. The funds from this round of financing will be used for the company.Magnetic Wave Knife SeriesNew product R&D, clinical trials, certification applications, and IPO coaching, etc.
FlexiLin Technology
R&D Field: EEG Sleep Monitor, etc.
On October 9, Rouling Technology announced that it had recently completed a Pre-A round of financing worth tens of millions of yuan. This round of financing was led byShanghai Lanwan Sci-Tech Group Leads Investment, Zheng He Xiang, Former Bain Capital PartnerFollowing the investment, there are two industrial capital entities involved in financial investment that will not be disclosed for the time being. Founded in 2020, Rouling Technology is committed to creating infrastructure for "brain-computer interface + human-computer interaction" and has already made achievements in the EEG field.Medical-Grade Flexible EEG Sleep Patch Series, the first-generation EEG sleep monitoring device product has been approved for marketing. The company will also developInvasive Flexible Brain-Computer Interface Products, Electromyography Productsetc.
R&D Field: Flexible Brain-Computer Interface DevicesOctober 24, Symbionics announced the completionByKunlun CapitalExclusively InvestedRMB 30 million in angel round funding. Hex Tech, established in 2023, is a brain-computer interface startup company focused on research and development.Flexible Brain-Computer Interface Device。It is reported that,The company's flexible electrode technology has currently achieved long-term stable collection of high-quality, single-cell resolution neural signals. It can evade immune rejection in living organisms, and the implanted electrodes exhibit high biocompatibility and neural interface stability, addressing many issues associated with traditional rigid electrodes.R&D Field: Neuromodulation Medical Devices
News on October 25: LeadMed Innovations announced the completion of an over RMB 100 million Series A+ round of financing. This round of financing was led byFortune Morning CapitalLeading investment,Wuxi Zhaoyu LifengFollow-up Investment.LeadMed Innovation was founded in 2016,ByExpert in the Field of NeuromodulationAcademician Han Jishengand the Academic Leader of the Chinese Pain SocietyProfessor Fan BifaServe as the chief scientist for an innovative wireless-powered neuromodulation medical device R&D company, focusing on the fields of neuromodulation and pain management. It is reported that the company’sWireless Power-Carrying ImplantSpinal Cord Stimulation (SCS)ProductAddressed the complexity of surgical procedures, overcame the clinical application limitations of traditional active implantable neuroelectric stimulation products, eliminated the constraints of traditional implantable pulse generators and battery efficiency limitations, and reduced issues such as electrode displacement. This wireless-powered SCS product is about to enter the clinical trial stage.R&D Field: Precision Interventional Diagnostic and Therapeutic Products for Pan-Vascular Applications
On October 26, Saihe Medical announced the completion of a Series B financing round exceeding 200 million RMB.Led by Yuexiu Industrial Fund and Jianxin Equity, Cornerstone Capital followed on the investment, original shareholdersTencent Investment, Eight Roads Capital, Yahu InvestmentContinuously intensifying.Saihe MedicalEstablished in 2020,In the field of precise interventional diagnosis and treatment for coronary, peripheral, structural heart disease, and electrophysiologyDeveloped coronary artery intravascular shock wave treatment system, peripheral artery intravascular shock wave treatment system, intracardiac ultrasound imaging system (ICE system), intravascular ultrasound and other泛vascular active interventional systems.Innovative products. Developed byThe ICE system has completed its clinical registration and entered the registration application phase. This product has alreadyApproved to enter the NMPA Innovative Medical Device Special Review Process (also known as the Green Channel) in China.
In addition to the aforementioned companies, other innovative medical device companies also completed financing in October this year. Due to space limitations, this article will not introduce them one by one. It is hoped that with the support of capital, these companies can accelerate the R&D progress of innovative products and bring new treatment options to a wide range of patients as soon as possible.
References: (Swipe up and down to view)
[1] RoboCT Receives Investment from Pappas Capital, Focusing on Exoskeleton Robot Technology for Rehabilitation and Health Care.Retrieved Oct 7，2023. From https://mp.weixin.qq.com/s/5jqeOiUV89c6uEn70G9CWw
[2] Riemann Conjecture | Nanjing Oxygen Rich Intelligent Medical Technology Co., Ltd. Completes First Seed Round Financing, Riemann Conjecture Serves as Exclusive Financial Advisor for This Round.Retrieved Oct 8，2023. From https://mp.weixin.qq.com/s/bCs3Pz_Matmm5J5kS7JpZA
[3] LifeShield Medical Completes Over 100 Million Yuan in Financing, Accelerating Commercialization of Heart and Lung Failure Therapies; Sherpa Investment and Yuanfeng Capital Lead the Round.Retrieved Oct 8，2023. From https://mp.weixin.qq.com/s/ZUweVAHUSFiG984ldEyC-A
[4] Good News | RoboCT Completes Pre-A Round Financing of Tens of Millions Yuan, Accelerating Clinical and Commercial Applications. Retrieved Oct 9，2023. From https://mp.weixin.qq.com/s/xxtceKCjIscSP2uhgHF_-g
[5] [First Release] Shen De Non-Invasive Era Completes Nearly 200 Million RMB D-Round Financing, Initiating a New Era of Precision Non-Invasive Medical Treatment. Retrieved Oct 10，2023. From https://mp.weixin.qq.com/s/qgc01FBKdF2xCOHxA2jbcQ
[6] Heze Technology Completes 30 Million Yuan Angel Round Financing, Exclusively Invested by Kunlun Capital | Kunlun Capital Portfolio. Retrieved Oct 24, 2023, From https://mp.weixin.qq.com/s/NYAfdIccEqaV02H-_rsgtA
[7] Huagai Family | LeadMed Tech Completes Over 100 Million Yuan in Series A+ Financing, Building a Wireless Implantable Neurostimulation Technology Platform. Retrieved Oct 25，2023, From https://mp.weixin.qq.com/s/aWsyN7MNmStQLPimuLygng
[8] Heavyweight | Saihe Medical Completes Over 200 Million RMB in Series B Financing.Retrieved Oct 26，2023. From https://mp.weixin.qq.com/s/YryM-MJPM5KEsZ2V9Sclcw
This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media circles, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please contact us via a message on the "MedView" WeChat Official Account. For other collaboration inquiries, please contact wuxi_media@wuxiapptec.com.
Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes the views in the article. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规医院.
